# Test Results: literature/paper-summary.md

> ⚠️  Raw model output captured automatically by the cross-model test harness on 2026-06-23.
> This output is **not yet verified**. An author must read the output and set the
> assessment below before this counts as a tested result (see CLAUDE.md, Hard Rules).

## Test Metadata
- **Prompt:** literature/paper-summary.md
- **Model:** claude-sonnet-4.6
- **Model ID (pinned):** claude-sonnet-4-6
- **Endpoint:** native
- **Date:** 2026-06-23
- **Tester:** cross-model-harness
- **Assembly strategy:** concat
- **Temperature:** 0.0

## Test Input Used
Standard test input from prompt file (`## Test Input`).

## Filled Prompt
```
Context: I am a {RESEARCHER_ROLE} reviewing literature on {RESEARCH_TOPIC}. I need a structured summary of the following paper for my literature notes.

Paper text:
{PAPER_TEXT}

Task: Summarize this paper using the following structure.

1. **Citation**: Format as: Authors (Year). Title. Journal.

2. **Central Finding**: One to two sentences stating the main result or conclusion. Be specific about what was found, not just what was studied.

3. **Research Question/Hypothesis**: What question did the authors set out to answer?

4. **Methods Overview**:
   - Study system/organism
   - Key techniques or approaches
   - Sample size and design (if applicable)

5. **Key Results**: Three to five bullet points of specific findings. Include effect sizes or quantitative results where available.

6. **Limitations**: What limitations do the authors acknowledge? What limitations are apparent but not discussed?

7. **Open Questions**: What questions remain unanswered? What would logical next steps be?

8. **Relevance to My Work**: How might this paper inform {SPECIFIC_ASPECT_OF_YOUR_RESEARCH}?

Constraints:
- Use only information present in the paper—do not add context from other sources
- If a section cannot be completed from the available text, state "Not available in provided text"
- Distinguish between what authors claim and what the data support
- Note if sample sizes or effect sizes are not reported

Output format: Use the numbered structure above with headers in bold.

Context: I am a microbiome researcher reviewing literature on diet-microbiome interactions. I need a structured summary of the following paper for my literature notes.

Paper text:
[SIMULATED PAPER EXCERPT]

Title: Short-chain fatty acid production is reduced in patients with irritable bowel syndrome and correlates with symptom severity

Authors: Chen Y, Roberts K, Nakamura T, Wilson D, et al.

Abstract: Background: Irritable bowel syndrome (IBS) affects 10-15% of the global population, but its etiology remains unclear. Gut microbiome alterations have been implicated, yet functional consequences are understudied. We investigated short-chain fatty acid (SCFA) production in IBS patients versus healthy controls.

Methods: We recruited 45 IBS patients (Rome IV criteria) and 40 age- and sex-matched healthy controls. Fecal samples were analyzed using 16S rRNA gene sequencing (V4 region, Illumina MiSeq) and gas chromatography for SCFA quantification. Symptom severity was assessed using the IBS Severity Scoring System (IBS-SSS).

Results: IBS patients showed significantly reduced fecal butyrate (p=0.003) and propionate (p=0.02) compared to controls, while acetate levels were similar. Butyrate concentration negatively correlated with IBS-SSS scores (r=-0.42, p=0.004). Patients with IBS showed depletion of Faecalibacterium prausnitzii and Roseburia species, both known butyrate producers. No significant differences were observed in alpha diversity metrics (Shannon, observed ASVs).

Discussion: Our findings suggest that reduced SCFA production, particularly butyrate, may contribute to IBS symptoms. The correlation with symptom severity supports a functional role for these metabolites. Limitations include the cross-sectional design, which cannot establish causality, and recruitment from a single clinical center. Future longitudinal studies and intervention trials targeting SCFA production are warranted.

Relevance aspect: how microbial metabolites affect gut health in my mouse models

**Constraints:**
- Use only information present in the paper—do not add context from other sources
- If a section cannot be completed from the available text, state "Not available in provided text"
- Distinguish between what authors claim and what the data support
- Note if sample sizes or effect sizes are not reported
```

## Model Output
```
# Literature Note: Chen et al. — IBS and SCFA Production

---

**1. Citation**

Chen Y, Roberts K, Nakamura T, Wilson D, et al. (Year not provided in excerpt). Short-chain fatty acid production is reduced in patients with irritable bowel syndrome and correlates with symptom severity. *Journal not provided in excerpt.*

---

**2. Central Finding**

IBS patients showed significantly reduced fecal butyrate and propionate concentrations compared to healthy controls, and butyrate levels negatively correlated with symptom severity scores. The authors interpret this as suggesting a functional role for SCFA deficiency in IBS, though the cross-sectional design means causality cannot be established from these data alone.

---

**3. Research Question/Hypothesis**

The authors set out to investigate whether SCFA production is altered in IBS patients relative to healthy controls, and whether any such differences relate to symptom severity. The implicit hypothesis is that gut microbiome alterations in IBS have measurable functional metabolic consequences.

---

**4. Methods Overview**

- **Study system/organism:** Human clinical cohort — IBS patients diagnosed by Rome IV criteria and age- and sex-matched healthy controls
- **Key techniques or approaches:**
  - 16S rRNA gene sequencing (V4 region, Illumina MiSeq) for microbiome composition
  - Gas chromatography for fecal SCFA quantification
  - IBS Severity Scoring System (IBS-SSS) for symptom assessment
  - Correlation analysis between butyrate and symptom scores
- **Sample size and design:** 45 IBS patients and 40 healthy controls; cross-sectional design; single clinical center recruitment

---

**5. Key Results**

- Fecal butyrate was significantly reduced in IBS patients compared to controls (p = 0.003); effect size not reported
- Fecal propionate was also significantly reduced in IBS patients (p = 0.02); effect size not reported
- Acetate levels did not differ significantly between groups
- Butyrate concentration negatively correlated with IBS-SSS symptom severity scores (r = −0.42, p = 0.004), indicating a moderate inverse relationship
- IBS patients showed depletion of *Faecalibacterium prausnitzii* and *Roseburia* species relative to controls; no quantitative abundance differences are reported in the excerpt
- Alpha diversity (Shannon index, observed ASVs) did not differ significantly between groups — **notably, compositional differences appear to be present without overall diversity loss**

> ⚠️ **Note on effect sizes:** Beyond the correlation coefficient (r = −0.42) and p-values, the paper does not appear to report effect sizes (e.g., Cohen's d) or absolute SCFA concentration differences in the provided excerpt.

---

**6. Limitations**

**Acknowledged by authors:**
- Cross-sectional design precludes causal inference — it is unknown whether reduced SCFAs contribute to IBS or result from it
- Single clinical center recruitment limits generalizability

**Apparent but not discussed in the provided excerpt:**
- The relatively modest sample size (n = 45/40) may limit statistical power, particularly for subgroup analyses not reported here
- 16S rRNA sequencing identifies taxa but cannot directly measure functional capacity; shotgun metagenomics or metatranscriptomics would more directly link microbial composition to SCFA production
- IBS is a heterogeneous condition (subtypes: IBS-C, IBS-D, IBS-M) — subtype stratification is not mentioned in the excerpt, which could obscure differential patterns
- Diet was not mentioned as a covariate; dietary fiber intake is a major driver of SCFA production and represents a potential confound
- The correlation (r = −0.42) is moderate and leaves substantial variance in symptom severity unexplained

---

**7. Open Questions**

- **Causality:** Does reduced SCFA production drive IBS symptoms, or do IBS-associated gut changes (e.g., motility, inflammation) reduce SCFA-producing bacteria? Longitudinal and interventional designs are needed
- **Mechanistic pathway:** Through what mechanism(s) would reduced butyrate worsen IBS symptoms — epithelial barrier function, visceral sensitivity, immune modulation?
- **Intervention potential:** Would dietary or probiotic interventions that restore butyrate production (e.g., fiber supplementation, *F. prausnitzii* supplementation) reduce symptom severity?
- **IBS subtype specificity:** Do SCFA differences vary across IBS subtypes?
- **Acetate:** Why was acetate unaffected while butyrate and propionate were reduced? This selectivity is not explained in the excerpt
- Authors explicitly call for future longitudinal studies and intervention trials

---

**8. Relevance to My Work**

*Regarding how microbial metabolites affect gut health in mouse models:*

This paper provides **human correlational evidence** that butyrate and propionate deficiency associates with gut dysfunction, which could inform the design and interpretation of mouse model experiments in several ways:

- The **butyrate–symptom correlation (r = −0.42)** offers a human benchmark; your mouse models could be used to test whether experimentally manipulating butyrate levels (e.g., via dietary fiber, sodium butyrate supplementation, or colonization with *F. prausnitzii*) produces measurable gut health outcomes — establishing the causal direction this study cannot
- The **depletion of *F. prausnitzii* and *Roseburia*** identified here could guide targeted colonization experiments in germ-free or gnotobiotic mouse models to isolate the contribution of these specific taxa to SCFA production and gut physiology
- The **lack of alpha diversity differences** despite functional metabolic changes is a useful reminder that diversity metrics alone may be insufficient readouts in your mouse experiments — SCFA quantification via GC (as used here) may be a valuable addition to your analytical pipeline
- The **cross-sectional limitation** of this human study is precisely what mouse models are well-positioned to address; a longitudinal or interventional mouse study could provide the mechanistic and causal evidence this paper calls for

> ⚠️ **Translational caveat:** Mouse and human gut microbiomes differ substantially in composition; findings regarding specific taxa (*F. prausnitzii*, *Roseburia*) may not translate directly, and this paper provides no mouse data.
```

## Overall Assessment
- **Recommendation:** Pass
- **Notes:**
## Verification Steps Tested
_Which verification requirements from the prompt were checked, and results._
